TVGN Tevogen Bio Holdings Inc.
8-K Current Report
Filed: March 4, 2026
Health Care
Biological Products, (No Diagnostic Substances)Tevogen Bio Holdings Inc. (TVGN) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 3.03: Material Modification to Rights of Security Holders
- Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 3.03 · Material Modification to Rights of Security Holders
- • Bylaws/charter amended — full details under Item 5.03 of this same 8-K filing
- • Investors should review Item 5.03 for specifics on what shareholder rights or corporate governance provisions were changed
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- • 1-for-50 reverse split effective March 6, 2026; reduces shares outstanding from ~202.4M to ~4.05M
- • Authorized share count stays at 800M, dramatically increasing the ratio of authorized-to-outstanding shares — creates large future dilution capacity
Item 7.01 · Regulation FD Disclosure
- • Tevogen Bio (TVGN) announced a reverse stock split via press release dated March 4, 2026
- • Reverse splits typically signal share price was below exchange minimum listing requirements — a red flag for shareholders
Other Tevogen Bio Holdings Inc. 8-K Filings
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.